Boston adjusts Q3 after hefty Guidant charges
This article was originally published in Clinica
Executive Summary
Boston Scientific has been forced to adjust its Q3 financial results after agreeing to pay $296m settle allegations of misdemeanour against its Guidant subsidiary.